Growing interest in the dedicated osteosarcoma program since its official launch at the end of March 2023 with a 33% increase in the number of centers
16 participating centers in 7 countries
Successful participation in the congress of the European Society of Veterinary Oncology
Gosselies (Wallonia, Belgium), June 15, 2023 – 7:30 a.m. CEST — TheraVet (ISIN code: BE0974387194 – mnemonic: ALVET), a pioneering biotechnology company in the treatment of osteoarticular diseases in companion animals, provided an update on the dedicated program to osteosarcoma and its participation in the ESVONC congress (European Society of Veterinary Oncology).